591 / 1498
Overall Survival by induction regimen
100
80
60
40
20
0
Patients (%)
0
1
2
3
4
5
R-CHOP 93.2% (91.2–94.7%)
R-FCM 74.1% (57.9–84.8%)
R-CVP 88.3% (83.4–91.9%)
Time (years)
42 months
R-CHOP n = 881
R-CVP n = 268
R-FCM n = 44
p
< 0.0001
Second malignancies seen in 23 patients (2%, 3% and 8% in R-CVP,
R-CHOP and R-FM, respectively).
R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-
stage follicular lymphoma: Final results of FOLL05 trial from the
Fondazione Italiana Linfomi (FIL).Federico et al
J Clin Oncol 2013